|
|
||||||||
CUTTING EDGE |




* Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany;
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa;
Unité Mixte de Recherche 7175, Centre National de la Recherche Scientifique, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, France;
TeGenero Immunotherapeutics, Würzburg, Germany; and
¶ Institut für Multiple Sklerose Forschung, Göttingen, Germany
CD28 and CTLA-4 are the major costimulatory receptors on naive T cells. But it is not clear why CD28 is monovalent whereas CTLA-4 is bivalent for their shared ligands CD80/86. We generated bivalent CD28 constructs by fusing the extracellular domains of CTLA-4 or CD80 with the intracellular domains of CD28. Bivalent or monovalent CD28 constructs were ligated with recombinant ligands with or without TCR coligation. Monovalent CD28 ligation did not induce responses unless the TCR was coligated. By contrast, bivalent CD28 ligation induced responses in the absence of TCR engagement. To extend these findings to primary cells, we used novel superagonistic and conventional CD28 Abs. Superagonistic Ab D665, but not conventional Ab E18, predominantly ligates CD28 bivalently at low CD28/Ab ratios and induces Ag-independent T cell proliferation. Monovalency of CD28 for its natural ligands is thus essential to provide costimulation without inducing responses in the absence of TCR engagement.
This article has been cited by other articles:
![]() |
N. Beyersdorf, X. Ding, T. Hunig, and T. Kerkau Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease Blood, November 12, 2009; 114(20): 4575 - 4582. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Beyersdorf, X. Ding, G. Blank, K. M. Dennehy, T. Kerkau, and T. Hunig Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody Blood, November 15, 2008; 112(10): 4328 - 4336. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Teft and J. Madrenas Molecular Determinants of Inverse Agonist Activity of Biologicals Targeting CTLA-4 J. Immunol., September 15, 2007; 179(6): 3631 - 3637. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Dennehy, F. Elias, S.-Y. Na, K.-D. Fischer, T. Hunig, and F. Luhder Mitogenic CD28 Signals Require the Exchange Factor Vav1 to Enhance TCR Signaling at the SLP-76-Vav-Itk Signalosome J. Immunol., February 1, 2007; 178(3): 1363 - 1371. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |